shortagewatch

Home / Companies / Takeda

Company family · HQ JP

Takeda: medicine shortages

4502 / TAK · Tokyo / NYSE

As of 2 Nov 2026, 76 Takeda products have a reported shortage across 10 countries, covering 10 medicines.

Products short76rank #25 of 464
Medicines10active ingredients
Countries10/16
New in 90 days8-3 vs market pace
Typical duration3.3 yearsmedian so far
Manufacturing6%demand-driven 35%

Where

United States20Canada1Italy14Spain2Austria24Switzerland2Czechia1Norway2Sweden1Japan9

Which therapeutic classes

Anti-infectives30Nervous system24Cancer and immune system4Digestive tract and metabolism3Blood2Systemic hormones2

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
TakedaTakeda: Manufacturing problem 3 (4%)4%Takeda: Increased demand 18 (25%)25%Takeda: Active ingredient shortage 18 (25%)25%Takeda: Distribution or logistics 3 (4%)4%Takeda: Commercial decision or withdrawal 2 (3%)Takeda: Other 4 (5%)5%Takeda: Not stated 25 (34%)34%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

01235Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 3May: 3MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 3NovDec: 3Jan ’26: 1Feb: 1FebMar: 3Apr: 0May: 2MayJun: 3Jul: 1Aug: 1AugSep: 3Oct: 4Nov: 0Nov

Long-run trend in Canada

Canada dashboard
051015202017: 420172018: 720182019: 1520192020: 1220202021: 1420212022: 820222023: 820232024: 320242025: 420252026: 52026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Takeda76

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Takeda: 76 / 10Takeda

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Lisdexamfetamine1914 Jul 2023Not stated5/16
Immunoglobulins, Normal Human, for Extravascular Adm.1525 Nov 2020Active ingredient shortage3/16
Immunoglobulins, Normal Human, for Intravascular Adm.1010 Apr 2019Active ingredient shortage6/16
Carbamazepine319 Dec 2025Not stated5/16
Leuprorelin35 Jun 2026Increased demand5/16
Pantoprazole37 Oct 2026Increased demand9/16
Albumin21 Apr 2021Increased demand7/16
Hydrocortisone227 Jul 2026Not stated4/16
Ramelteon219 Mar 2026Not stated1/16
Anagrelide124 Sep 2026Not stated3/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.